What Is the Keytruda Colon Cancer Survival Rate?

In the largest randomized trial of Keytruda (pembrolizumab) for advanced colon cancer, patients with a specific tumor type lived roughly twice as long as those on standard chemotherapy. Five-year follow-up data from that trial showed a median overall survival of about 77.5 months with Keytruda compared to 36.7 months with chemotherapy. But this dramatic benefit applies only to tumors that are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), a subgroup that makes up a minority of all colorectal cancers. The survival picture depends heavily on which molecular category your tumor falls into, what stage it is, and whether certain genetic mutations are present.

The KEYNOTE-177 Trial and Its Headline Numbers

Almost everything known about Keytruda’s survival benefit in colon cancer comes from a single large trial called KEYNOTE-177. This study enrolled 307 patients with previously untreated metastatic colorectal cancer that tested MSI-H or dMMR, then randomly assigned them to receive either Keytruda alone or one of several standard chemotherapy regimens (with or without a targeted drug like bevacizumab or cetuximab).

The first major readout, after a median follow-up of about 32 months, showed that Keytruda roughly doubled the time patients lived without their cancer worsening. Median progression-free survival was about 16.5 months with Keytruda versus 8.2 months with chemotherapy.¹ At that point, overall survival data were still maturing and had not yet shown a clear statistical winner, though fewer deaths had occurred in the Keytruda group.

The final analysis, conducted at a median follow-up of roughly 44.5 months, told a more nuanced story. Median overall survival still had not been reached in the Keytruda arm, while the chemotherapy arm’s median was 36.7 months. The hazard ratio favored Keytruda, but the trial’s prespecified statistical bar for declaring superiority in overall survival was not met.² That sounds disappointing at first glance, but the reason is worth understanding. A large share of patients assigned to chemotherapy eventually crossed over to receive Keytruda or another immunotherapy after their cancer progressed, which effectively blurred the survival difference between the two arms. When people in the “chemotherapy group” later get the same drug being tested, the survival gap shrinks even if the drug genuinely works.

Five-Year Follow-Up Data

In late 2024, investigators published a five-year update from KEYNOTE-177 that filled in much of the picture the earlier analyses could not. With longer follow-up, median overall survival landed at 77.5 months in the Keytruda arm versus 36.7 months in the chemotherapy arm. The five-year overall survival rate was about 55% for Keytruda compared to roughly 44% for chemotherapy.³ That gap, more than six years of median survival in the Keytruda arm versus just over three years in the chemotherapy arm, is striking for metastatic colorectal cancer, where historical five-year survival rates with chemotherapy alone have been quite poor.

The progression-free survival advantage held up as well, remaining at about 16.5 versus 8.2 months. What the long-term data also hinted at, and what oncologists find particularly encouraging, is a flattening of the survival curve in the Keytruda arm. Some patients who responded to Keytruda appeared to remain in durable remission years later, suggesting a subset of people may achieve something close to long-term disease control.

Why MSI-H Status Is the Deciding Factor

Keytruda works by blocking PD-1, a protein on the surface of immune cells that tumors exploit to avoid being attacked. When PD-1 is blocked, T cells can recognize and destroy cancer cells more effectively. But this mechanism only helps when the tumor is already visible to the immune system, and that is where MSI-H status comes in.

MSI-H tumors have defects in their DNA repair machinery, which causes them to accumulate large numbers of mutations. Those mutations produce abnormal proteins that the immune system can potentially recognize as foreign. In effect, MSI-H tumors are covered in molecular red flags that immune cells can latch onto once the PD-1 brake is released. This is why Keytruda works so well in this group and barely works at all in the other group.⁴

The catch is that MSI-H or dMMR tumors represent only about 15% of all colorectal cancers. The remaining 85% are classified as microsatellite stable (MSS) or mismatch repair-proficient (pMMR). For this majority, Keytruda as a single agent has shown essentially no meaningful benefit.⁵ That is one of the most common misconceptions patients encounter: hearing about Keytruda’s impressive colon cancer results without realizing those results apply to a specific molecular subset, not to colon cancer in general.

What Happens for the MSS Majority

The fact that roughly 85% of colorectal cancer patients cannot benefit from Keytruda alone has driven intense research into combination strategies. Researchers are testing Keytruda alongside other drugs, hoping to convert “cold” MSS tumors into something the immune system can recognize.

One approach combines immunotherapy with a PARP inhibitor at low continuous doses. In preclinical work, a metronomic dose of the PARP inhibitor olaparib was highly synergistic with anti-PD-1 therapy, leading to tumor shrinkage in MSS models.⁶ This is still early-stage research, but it illustrates the general strategy: use another drug to damage tumor DNA or alter the tumor’s local immune environment, then unleash the immune system with a checkpoint inhibitor.

A clinical study comparing different combination strategies in MSS metastatic colorectal cancer found that a regimen called PRaG therapy (which combines a PD-1 inhibitor with radiation and a growth factor) achieved the highest response rate at 20% and the longest median progression-free survival at 4.5 months among the groups tested. However, none of the combinations significantly improved overall survival.⁷ To put that in context, a 4.5-month median PFS is a far cry from the 16.5 months seen with Keytruda in MSI-H disease. For MSS colon cancer, effective immunotherapy remains an unmet need.

Pseudoprogression, a phenomenon where tumors temporarily appear to grow on imaging before shrinking, has been discussed as a potential complication that could lead doctors to stop immunotherapy too early. But a study of MSS colorectal cancer patients treated beyond initial progression found zero cases of subsequent tumor shrinkage. The researchers concluded that pseudoprogression occurs so rarely in MSS colon cancer that continuing immunotherapy past progression is unlikely to help.⁸

How BRAF and KRAS Mutations Affect Response

Even within the MSI-H population, not all patients respond equally. The genetic mutations driving the tumor appear to influence how well Keytruda works, and two mutations get the most attention: BRAF and KRAS.

BRAF mutations, most commonly the V600E variant, are found in a significant fraction of MSI-H colorectal cancers. These tumors tend to be aggressive and carry a worse prognosis overall, but intriguingly, Keytruda has shown good efficacy regardless of BRAF mutation status in MSI-H patients. KRAS or NRAS mutations tell a different story: decreased benefit from Keytruda has been observed in patients whose MSI-H metastatic tumors carry these mutations.⁹ The reasons likely involve differences in how these mutations shape the tumor’s immune environment. BRAF-mutated MSI-H tumors tend to have denser immune cell infiltration, which gives the checkpoint inhibitor more to work with. KRAS-mutated tumors may create a more immunosuppressive local environment that partially counteracts the drug.

This is still an evolving area, and current guidelines do not exclude KRAS-mutated MSI-H patients from receiving Keytruda. But it does mean that a patient whose MSI-H tumor also carries a KRAS mutation may not see the same dramatic benefit reflected in the headline trial numbers.

Real-World Results Outside Clinical Trials

Clinical trials enroll carefully selected patients who tend to be younger and healthier than the average cancer patient. So it matters whether Keytruda’s benefits hold up in everyday practice. A real-world study of patients with dMMR or MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors found that median overall survival was not reached at the time of analysis, with an estimated survival rate at two years of about 57%.¹⁰ The three-month survival rate was about 87%, indicating that most patients at least tolerate the treatment in the short term.

These real-world numbers are broadly consistent with the trial data, which is reassuring. The two-year survival estimate of 57% tracks reasonably well with KEYNOTE-177’s five-year rate of about 55%, considering that real-world populations include older patients, those with more comorbidities, and people who might not have qualified for the trial. It suggests the trial results were not artificially inflated by patient selection to a degree that would mislead.

Keytruda Before Surgery for Earlier-Stage Disease

The survival numbers discussed so far all come from patients with metastatic, meaning stage IV, disease. But researchers are also exploring whether giving Keytruda before surgery in earlier-stage MSI-H colon cancer could improve outcomes or even eliminate the need for surgery altogether.

The RESET-C trial gave a single cycle of Keytruda to 84 patients with stage I through III MMR-deficient colon cancer before their planned surgery. Among those patients, 44% had a complete pathological response, meaning no viable cancer cells remained in the surgical specimen. At a median follow-up of about 18 months, only one patient had experienced a recurrence, resulting in disease-free and overall survival rates of 96% and 98%, respectively.¹¹

A smaller study of neoadjuvant Keytruda in localized dMMR or MSI-H solid tumors, which included colorectal cancers, found an even higher pathological complete response rate of 65% among patients who went on to surgery.¹² These results raise a provocative question: if immunotherapy can destroy the entire tumor before surgery, could some patients avoid the operation entirely? This organ-sparing approach is still experimental, and longer follow-up is needed to confirm that patients who skip surgery based on a clinical complete response do not relapse at higher rates. But the early data are generating real enthusiasm among oncologists who treat this disease.

Quality of Life on Keytruda Versus Chemotherapy

Survival numbers are the headliner, but how patients feel during treatment matters enormously. The KEYNOTE-177 trial included detailed quality-of-life assessments, and the results strongly favored Keytruda. By 18 weeks, patients on Keytruda reported clinically meaningful improvements in their overall quality of life compared to those on chemotherapy. Keytruda also significantly delayed the time to deterioration in physical functioning, social functioning, and fatigue.¹³

This is not a trivial finding. Standard chemotherapy regimens for colorectal cancer cause nausea, neuropathy (tingling or numbness in the hands and feet), and cumulative fatigue that worsens over months of treatment. Keytruda has its own side effects, including immune-related reactions where the activated immune system attacks healthy tissues like the thyroid, liver, or lungs. But the overall burden on daily life appears to be lighter. For patients weighing their options, the combination of longer survival and better day-to-day functioning during treatment makes a compelling case.

Cost-Effectiveness in the United States

Keytruda is expensive, and patients understandably wonder whether it represents good value. A cost-effectiveness analysis based on U.S. data found that first-line Keytruda for MSI-H or dMMR metastatic colorectal cancer cost about $381,735 over a lifetime horizon, compared to roughly $370,465 for standard chemotherapy. That difference of about $11,000 translated to an additional 1.6 quality-adjusted life years, yielding a cost per additional quality-adjusted life year of under $7,000.¹⁴ By conventional health-economic thresholds, that is considered highly cost-effective. Keytruda’s higher drug acquisition costs were partially offset by savings in drug administration, side-effect management, and subsequent treatments. In head-to-head comparisons with several common chemotherapy combinations, Keytruda either dominated (cost less and worked better) or was cost-effective by a wide margin.

These figures come from a modeling study and depend on assumptions about long-term outcomes, drug pricing, and treatment patterns. But they help explain why insurers in the U.S. generally cover Keytruda for this indication without excessive pushback: the survival gains are large enough that the math works out even at a high drug price.

The Gut Microbiome Connection

One of the more unexpected areas of research involves the bacteria living in a patient’s gut. A growing body of evidence suggests that the composition of the gut microbiome influences how well immunotherapy works across multiple cancer types, including colorectal cancer. Specific bacterial species appear to enhance the immune system’s response to checkpoint inhibitors, while others may dampen it. Researchers have proposed that the gut microbiota could serve as biomarkers to predict immunotherapy response and that modifying the microbiome might improve treatment outcomes.¹⁵

This is still largely at the research stage. There are no approved microbiome-based tests or treatments that reliably predict or enhance Keytruda’s effectiveness in colon cancer. But it is a plausible mechanism, and several clinical trials are exploring fecal microbiota transplantation or targeted probiotic interventions alongside immunotherapy. For patients, the practical takeaway is limited right now: maintaining a diverse, fiber-rich diet is generally recommended for gut health, but no one can yet prescribe a specific microbial cocktail to boost your odds with Keytruda.

How Keytruda Compares to Other Immunotherapies

Keytruda is not the only immune checkpoint inhibitor used in MSI-H colorectal cancer. The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is another approved first-line option. In a large trial, that combination reduced the risk of disease progression or death by about 38% compared to nivolumab alone, with an overall response rate of roughly 71% for the combination versus 58% for nivolumab alone. Median progression-free survival was not reached with the combination and was about 39 months with nivolumab monotherapy.

Head-to-head comparisons between Keytruda and the nivolumab-ipilimumab combination have not been conducted in a randomized trial, which makes it difficult to say definitively which is better. The combination likely produces higher response rates but also comes with more immune-related side effects, since it blocks two separate immune checkpoints. In practice, the choice often depends on the patient’s overall health, tolerance for side effects, and the treating oncologist’s preference. Both options represent a dramatic improvement over chemotherapy alone for MSI-H patients, and the survival curves from their respective trials look broadly similar, though cross-trial comparisons are notoriously unreliable.

Getting Tested and What the Results Mean

Given that the entire Keytruda survival benefit depends on MSI-H or dMMR status, getting tested is the most important practical step for any colon cancer patient considering immunotherapy. Current guidelines recommend universal testing of all colorectal cancers for mismatch repair status, typically through immunohistochemistry on the tumor tissue removed during biopsy or surgery. If the results are ambiguous, a follow-up PCR-based microsatellite instability test or next-generation sequencing can clarify the status.

About 15% of all colorectal cancers will test MSI-H or dMMR. The proportion is higher in earlier-stage disease and in tumors located on the right side of the colon. Patients diagnosed with right-sided colon cancer who are told their tumor is MSI-H are the ones most likely to see the survival benefits described above. Left-sided colon cancers and rectal cancers are less frequently MSI-H, though it does occur. If you have been diagnosed with colorectal cancer and have not been told your MSI or MMR status, ask your oncologist. It is a standard test, and the result could change your entire treatment plan.